Proteolytic antibodies activate factor IX in patients with acquired hemophilia

Blood

Volumn 117, Issue 7, 2011, Pages 2257-2264

  Wootla, Bharath ^a,b,c,i   Christophe, Olivier D ^d   Mahendra, Ankit ^a,b,c   Dimitrov, Jordan D ^a,b,c   Repessé, Yohann ^a,b,c   Ollivier, Véronique ^c   Friboulet, Alain ^e   Borel Derlon, Annie ^f   Levesque, Hervé ^g   Borg, Jeanne Yvonne ^g   Andre, Sebastien ^a,b,c   Bayry, Jagadeesh ^a,b,c   Calvez, Thierry ^a,h   Kaveri, Srinivas V ^a,b,c   Lacroix Desmazes, Sébastien ^a,b,c  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSERM   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e UNIVERSITÉ DE TECHNOLOGIE DE COMPIÈGNE   (France)

^f UNIVERSITÉ DE CAEN   (France)

^g ROUEN UNIVERSITY HOSPITAL   (France)

^h Laboratory of Catalysis in Organic Chemistry   (France)

ⁱ MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; IMMUNOGLOBULIN G;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; HEMOPHILIA; HUMAN; IN VITRO STUDY; MALE; PRIORITY JOURNAL; PROTEIN DEGRADATION; SURVIVAL;

EID: 79951817706     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-07-296103     Document Type: Article

References (36)

1. Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to factor VIII. Thromb Haemost. 1981;45(3):200-203. (Pubitemid 11081028)
2. Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, Villar A. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol. 2003;121(1):21-35. (Pubitemid 36461264)
3. Collins PW, Hirsch S, Baglin TP, et al. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. Blood. 2007;109(5):1870-1877. (Pubitemid 46348182)
4. Saint-Remy JM, Lacroix-Desmazes S, Oldenburg J. Inhibitors in haemophilia: pathophysiology. Haemophilia. 2004;10[suppl 4]:146-151. (Pubitemid 40050864)
5. Wootla B, Dasgupta S, Dimitrov JD, et al. Factor VIII hydrolysis mediated by anti-factor VIII autoantibodies in acquired hemophilia. J Immunol. 2008;180(11):7714-7720.
6. Castro O, Farber LR, Clyne LP. Circulating anti-coagulants against factors IX and XI in systemic lupus erythematosus. Ann Intern Med. 1972;77(4):543-548.
7. Kyriakou DS, Alexandrakis MG, Passam FH, et al. Acquired inhibitors to coagulation factors in patients with gastrointestinal diseases. Eur J Gastroenterol Hepatol. 2002;14(12):1383-1387. (Pubitemid 36054929)
8. Largo R, Sigg P, von Felten A, Straub PW. Acquired factor-IX inhibitor in a nonhaemophilic patient with autoimmune disease. Br J Haematol. 1974;26(1):129-140.
9. Ozsoylu S, Ozer FL. Acquired factor IX deficiency: a report of two cases. Acta Haematol. 1973;50(5):305-314.
10. Roberts HR. Acquired inhibitors to factor IX. N Engl J Med. 1970;283(10):543-544.
11. Gouyon JB, Seiller F, Deries X, Alison M, Lorenzini JL, Devilliers E. Inhibitors of factors VIII and IX in a child with Henoch-Schonlein syndrome. Am J Pediatr Hematol Oncol. 1985;7(4):376-377. (Pubitemid 16199400)
12. Reussi C, Altman R, Rouvier J, Maino R. Combined factor VIII and IX inhibitors in a girl. Thromb Diath Haemorrh. 1966;16(3):549-558.
13. Levesque H, Borg J, Goudemand J, et al. Evolutive follow-up of acquired hemophilia: SACHA study. About 82 cases [in French]. Rev Med Interne. 2006;27(suppl 3):S298-S299.
14. Kasper CK, Aledort LM, Counts RB. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh. 1975;34:869-872.
15. Lacroix-Desmazes S, Bayry J, Misra N, et al. The prevalence of proteolytic antibodies against factor VIII in hemophilia A. N Engl J Med. 2002;346(9):662-667. (Pubitemid 34815870)
16. Olson F, Hunt CA, Szoka FC, Vail WJ, Papahadjopoulos D. Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes. Biochim Biophys Acta. 1979;557(1):9-23. (Pubitemid 10245657)
17. Fraker PJ, Speck JC Jr. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. Biochem Biophys Res Commun. 1978;80(4):849-857. (Pubitemid 8305904)
18. Wootla B, Mahendra A, Dimitrov JD, et al. Factor VIII-hydrolyzing IgG in acquired and congenital hemophilia. FEBS Lett. 2009;583(15):2565-2572.
19. Christophe OD, Lenting PJ, Cherel G, et al. Functional mapping of anti-factor IX inhibitors developed in patients with severe hemophilia B. Blood. 2001;98(5):1416-1423.
20. Kessler CM. Acquired factor VIII autoantibody inhibitors: current concepts and potential therapeutic strategies for the future. Haematologica. 2000;85(10 suppl):57-61; discussion 61-53.
21. Refino CJ, Himber J, Burcklen L, et al. A human antibody that binds to the gamma-carboxyglutamic acid domain of factor IX is a potent anti-thrombotic in vivo. Thromb Haemost. 1999;82(3):1188-1195. (Pubitemid 29419741)
22. Scheiflinger F, Dockal M, Rosing J, Kerschbaumer RJ. Enhancement of the enzymatic activity of activated coagulation factor IX by anti-factor IX antibodies. J Thromb Haemost. 2008;6(2):315-322.
23. Butenas S, Orfeo T, Gissel MT, Brummel KE, Mann KG. The significance of circulating factor IXa in blood. J Biol Chem. 2004;279(22):22875-22882. (Pubitemid 38685588)
24. Takaki A, Enfield DL, Thompson AR. Cleavage and inactivation of Factor IX by granulocyte elastase. J Clin Invest. 1983;72(5):1706-1715. (Pubitemid 14229050)
25. Samis JA, Kam E, Nesheim ME, Giles AR. Neutrophil elastase cleavage of human factor IX generates an activated factor IX-like product devoid of coagulant function. Blood. 1998;92(4):1287-1296. (Pubitemid 28369042)
26. Samis JA, Ramsey GD, Walker JB, Nesheim ME, Giles AR. Proteolytic processing of human coagulation factor IX by plasmin. Blood. 2000;95(3):943-951. (Pubitemid 30062716)
27. Bauer KA, Kass BL, ten Cate H, Hawiger JJ, Rosenberg RD. Factor IX is activated in vivo by the tissue factor mechanism. Blood. 1990;76(4):731-736. (Pubitemid 20253288)
28. Lacroix-Desmazes S, Moreau A, Sooryanarayana, et al. Catalytic activity of antibodies against factor VIII in patients with hemophilia A. Nat Med. 1999;5(9):1044-1047. (Pubitemid 29439576)
29. Lacroix-Desmazes S, Wootla B, Dasgupta S, et al. Catalytic IgG from patients with hemophilia A inactivate therapeutic factor VIII. J Immunol. 2006;177(2):1355-1363. (Pubitemid 44036643)
30. Paul S, Volle DJ, Beach CM, Johnson DR, Powell MJ, Massey RJ. Catalytic hydrolysis of vasoactive intestinal peptide by human autoantibody. Science. 1989;244:1158-1162. (Pubitemid 19170484)
31. Ponomarenko NA, Durova OM, Vorobiev II, et al. Catalytic antibodies in clinical and experimental pathology: human and mouse models. J Immunol Methods. 2002;269(1):197-211.
32. Ponomarenko NA, Durova OM, Vorobiev II, et al. Autoantibodies to myelin basic protein catalyze site-specific degradation of their antigen. Proc Natl Acad Sci U S A. 2006;103(2):281-286. (Pubitemid 43122392)
33. Belogurov AA Jr, Kurkova IN, Friboulet A, et al. Recognition and degradation of myelin basic protein peptides by serum autoantibodies: novel biomarker for multiple sclerosis. J Immunol. 2008;180(2):1258-1267.
34. Li L, Paul S, Tyutyulkova S, Kazatchkine MD, Kaveri S. Catalytic activity of anti-thyroglobulin antibodies. J Immunol. 1995;154:3328-3332.
35. Lacroix-Desmazes S, Bayry J, Kaveri SV, et al. High levels of catalytic antibodies correlate with favorable outcome in sepsis. Proc Natl Acad Sci U S A. 2005;102(11):4109-4113. (Pubitemid 40388563)
36. Wootla B, Nicoletti A, Patey N, et al. Hydrolysis of coagulation factors by circulating IgG is associated with a reduced risk for chronic allograft nephropathy in renal transplanted patients. J Immunol. 2008;180(12):8455-8460.